Zostavax

Zostavax Campaign Details

Prices listed are the current retail value and may be higher or lower based on availability, size of budget, demand, volatility and additional filters.

  • Zostavax lead
    Call for pricing
  • Zostavax signed
    Call for pricing

Zostavax Vaccine Criteria

  • Treated with Zostavax Shingles Vaccine between 2010 and Present
  • Current age is 50 or older
  • Suffered one of the following injuries after vaccination
    • Varicella Pneumonia
    • Permanent Blindness
    • Encephalitis (brain inflammation)
    • Meningitis
    • Guillain-Barre Syndrome
    • Vasculitis
    • Acute Disseminated Encephalomyelitis (ADEM)
    • Diagnosed Heart Failure
    • Death
    • Recurrence of Shingles
  • No attorney representation

Zostavax Background Information

Issues

The Zostavax shingles vaccine for people over 50 years of age that has less than a 50% success rate. Further, though approved by the FDA in 2006, Merck failed to warn that the vaccine could actually cause patients to develop shingles, and did not update this information onto the warning label until December 2014.

FDA

reports that Zostavax side effects list includes: shingles, chickenpox, rash, hives, headache, fever, nausea, joint pain, muscle pain and eye disorders (including necrotizing retinitis). It is believed that Zostavax can cause even more serious complications, such as blindness, hearing loss, paralysis, brain damage, neurological diseases (including encephalitis), herpic neuralgia (nerve disorder), postherpetic neuralgia (“PHN” – pain after shingles blister gone), myelitis (spinal cord inflammation), Bell’s Palsy (facial paralysis), liver failure, cardiovascular event, congestive heart failure, vasculitis and death

MDL 2848

Eastern District of Pennsylvania, Judge Harvey Bartle III. Additionally, claims have been centralized into an MCL in New Jersey. The consolidated proceedings will be managed by State Superior Court Judge James F. Hyland.

Manufacturer

Merck & Co

Timeline of Events

  • April 2000 : Medical journal “Nature Medicine” warns that live varicella zoster virus can reactivate.
  • June 2005 : Merck’s Shingles Prevention Study reports that their vaccine is safe for patients.
  • May 2006 : FDA approves Zostavax for shingles prevention for patients 60 and older.
  • March 2008 : Merck publishes Zostavax safety study that makes the claim that their vaccine is completely safe and effective.
  • March 2011 : FDA approves Zostavax for shingles prevention for patients 50 and older.
  • September 2015 : Adverse Event Reporting System has more than 1000 reports of serious side effects including 36 deaths.
  • March 2017 : CDC issues a recommendation for “Shingrix” instead of Zostavax due to the high number of reported injuries by Zostavax patients.
  • February 2018 : CDC updates warning label indicating that Zostavax may actually cause shingles rather than provide prevention.
  • August 2018 : JPML is established to consolidate the Zostavax litigation for all failure to warn lawsuits.

CONTACT US

We welcome you to contact Mass Torts USA for more information
about our products and services.